FY2024 EPS Estimates for Allakos Raised by Leerink Partnrs

Allakos Inc. (NASDAQ:ALLK - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Allakos in a report released on Thursday, November 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($1.19) for the year, up from their previous forecast of ($1.24). The consensus estimate for Allakos' current full-year earnings is ($1.20) per share. Leerink Partnrs also issued estimates for Allakos' Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.63) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.52) EPS and FY2028 earnings at ($0.48) EPS.

Allakos (NASDAQ:ALLK - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01.

ALLK has been the topic of several other reports. Jefferies Financial Group reduced their price target on Allakos from $1.50 to $1.00 and set a "hold" rating on the stock in a report on Thursday, July 18th. JMP Securities restated a "market outperform" rating and set a $3.00 target price on shares of Allakos in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $1.67.

Allakos Stock Up 11.1 %

Shares of NASDAQ ALLK traded up $0.15 during midday trading on Monday, reaching $1.50. 650,889 shares of the company were exchanged, compared to its average volume of 840,517. The stock's 50-day moving average price is $0.81 and its 200-day moving average price is $0.93. The stock has a market cap of $134.02 million, a P/E ratio of -0.74 and a beta of 1.03. Allakos has a one year low of $0.54 and a one year high of $3.41.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Point72 DIFC Ltd bought a new stake in shares of Allakos in the 2nd quarter worth $25,000. Cubist Systematic Strategies LLC bought a new position in shares of Allakos in the second quarter valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Allakos during the second quarter valued at approximately $112,000. BNP Paribas Financial Markets boosted its position in Allakos by 1,041.1% in the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company's stock worth $259,000 after purchasing an additional 187,640 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Allakos by 11.9% during the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company's stock valued at $519,000 after purchasing an additional 84,750 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.